Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

IMPORTANCE: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell tr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Netw Open
Egile Nagusiak: Wu, Hengwei, Shi, Jimin, Luo, Yi, Tan, Yamin, Zhang, Mingming, Lai, Xiaoyu, Yu, Jian, Liu, Lizhen, Fu, Huarui, Huang, He, Zhao, Yanmin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2021
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841467/
https://ncbi.nlm.nih.gov/pubmed/33502484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.34750
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak